Anzeige
Meldung des Tages: Unter dem Radar, voll finanziert: Beginnt jetzt der nächste Gold-Run?

Avidity Biosciences News

Aktie
WKN:  A2P5NK ISIN:  US05370A1088 US-Symbol:  RNAM Branche:  Biotechnologie Land:  USA
Keine aktuellen Kursdaten verfügbar
Depot/Watchlist
Marktkapitalisierung *
7,37 Mrd. €
Streubesitz
-
KGV
-16,07
Index-Zuordnung
-

Avidity Biosciences News

15.09.25 - PR Newswire
Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire
11.09.25 - PR Newswire
Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock
Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock PR Newswire
10.09.25 - PR Newswire
Avidity Biosciences Announces Proposed Public Offering of Common Stock
Avidity Biosciences Announces Proposed Public Offering of Common Stock PR Newswire
10.09.25 - PR Newswire
Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44
Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People ...
27.08.25 - PR Newswire
Avidity Biosciences to Participate in Upcoming Investor Conferences
Avidity Biosciences to Participate in Upcoming Investor Conferences PR Newswire
07.08.25 - PR Newswire
Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights
Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights PR Newswire
28.07.25 - PR Newswire
Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission
Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-​desiran) for Treatment of DM1 and Provides ...
23.07.25 - PR Newswire
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 ...
11.06.25 - PR Newswire
Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress
Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD ...
09.06.25 - PR Newswire
Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants
Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in ...
09.06.25 - PR Newswire
Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD
Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in ...
21.05.25 - PR Newswire
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
08.05.25 - PR Newswire
Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights
Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights PR Newswire
06.05.25 - PR Newswire
Avidity Biosciences to Participate in Upcoming Investor Conference
Avidity Biosciences to Participate in Upcoming Investor Conference PR Newswire
21.04.25 - PR Newswire
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire

Newssuche

Videos

newspaper
07.04.26 +4,00%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: VJ9H40 Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »